CSL is a century-old company and a darling among healthcare stocks, having delivered a 15% annual return over the past 10 years.
Currently, investors are spooked by three risks that are getting lots of attention.
Risk 1: Weight-loss drugs
Ozempic improves glycaemic control and can be used 'off label' to assist weight loss.
While the drug has been around for years, it's making headlines because researchers are finding new applications for it and easier ways to administer it.
The risk that Ozempic-like drugs, known as GLP-1 agonists, pose to CSL can be split into broad and narrow effects.
On the broad side, Ozempic helps people lose weight by reducing appetite. Ozempic is currently very expensive, but we can imagine a future where the government subsidises the drug as a way to improve the population's overall health and take pressure off stressed healthcare budgets.
The relevance to CSL is that its sprawling network of plasma collection centres tends to focus on lower-income neighbourhoods.
However, individuals with lower incomes also face a higher risk of being overweight, so this demographic may benefit from Ozempic disproportionately.
If people on Ozempic spend less on food, and their discretionary incomes subsequently rise, the pool of willing plasma donors may decline, or CSL may need to increase donor fees to compensate.
We consider this scenario unlikely, but Ozempic could disrupt some of CSL's products directly, including in its Vifor division - chiefly iron and other therapies used by patients with chronic kidney disease (CKD) and its nephrology and cholesterol drugs.
Diese Geschichte stammt aus der December/January 2023-Ausgabe von Money Magazine Australia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der December/January 2023-Ausgabe von Money Magazine Australia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Is the public market shrinking?
Australia needs a healthy stock market to give companies access to funds and to allow retail investors to build wealth.
India: three steps to transformation
Massive investment and extensive reforms turbocharge the economy.
From rags to riches in style
Rich Tran sported a bowl cut until he was 14 years old and had no intention of becoming a hairdresser.
BANKING OUTLOOK: It pays to be disloyal
THE BIG QUESTIONS FOR 2024
WORKING HARD FOR THE MONEY
This year, Money magazine rounded up nine of our most talented writers and tasked them with reporting on why exactly, in specific detail, these products or businesses are the most beneficial for our readers.
Signs of life in IPO drought
Improved investor confidence and lower economic volatility could set the stage for a bounceback in company listings
Biotech giant stumbles
CSL faces some big challenges, but the long-term prognosis is more encouraging
Another day of reckoning
With economic history pointing to a recession in 2024, investors should go on the defensive
Investing by colours, not numbers
If you work out your personality type, your goals become obvious and you can invest according to your archetype
There is such a thing as a free lunch
The Federal government is waiting to give your super a $500 boost... come and get it!